Name: Larimar Therapeutics, Inc. (LRMR) Financial Statements
Creator: FinSpry

Larimar Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Larimar Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	73.28	27.67	24.25	38.40	31.41
Selling, General & Administrative	17.61	14.09	12.28	12.07	11.40
Operating Expenses	90.89	41.76	36.53	50.47	42.80
Operating Income	-90.89	-41.76	-36.53	-50.47	-42.80
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	10.29	-4.81	1.17	0.17	0.32
Income
Income Before Tax	-80.60	-36.95	-35.36	-50.64	-42.48
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-80.60	-36.95	-35.36	-50.64	-42.48
Net Income - Continuous Operations	-80.60	-36.95	-35.36	-50.64	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-90.57	-36.64	-36.21	-50.14	-42.65
EBIT	-80.60	-36.95	-36.53	-50.47	-42.80
Depreciation & Amortization	0.32	0.31	0.32	0.33	0.16
Earnings Per Share
Basic EPS	-1.00	-1.00	-1.00	-3.00	-4.00
Diluted EPS	-1.00	-1.00	-1.00	-3.00	-4.00
Basic Shares Outstanding	61.26	43.90	25.76	17.16	11.88
Diluted Shares Outstanding	61.26	43.90	25.76	17.16	11.88